This inventor holds 4 USPTO granted patents. Top assignees: Bionumerik Pharmaceuticals, Inc., Other. Active years: 2000-2001.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2000-2001
Title: Seetharamulu Peddaiaghari: Innovator in Diabetic Treatment
Introduction
Seetharamulu Peddaiaghari is a notable inventor based in San Antonio, TX (US). He has made significant contributions to the field of medical treatment, particularly in addressing complications arising from diabetes. With a total of 4 patents to his name, his work focuses on innovative methods to improve patient care.
Latest Patents
Among his latest patents, Peddaiaghari has developed a method for treating diabetic ophthalmopathy. This invention involves administering an effective amount of a thiol or reducible disulfide compound to patients in need of treatment. Additionally, he has created a method for treating diabetic angiopathy, which similarly utilizes a thiol or reducible disulfide compound to aid patients suffering from this condition.
Career Highlights
Throughout his career, Peddaiaghari has worked with various organizations, including Bionumerik Pharmaceuticals, Inc. His experience in the pharmaceutical industry has allowed him to focus on developing effective treatments for diabetes-related complications.
Collaborations
Some of his notable coworkers include Frederick H Hausheer and Aulma Parker. Their collaboration has contributed to the advancement of research and development in the field of diabetic treatment.
Conclusion
Seetharamulu Peddaiaghari's innovative work in treating diabetic complications showcases his dedication to improving patient outcomes. His patents reflect a commitment to advancing medical science and providing effective solutions for those affected by diabetes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile